Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

The summary for the Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed): Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites grant applications proposing exploratory research projects focused on further development and technical validation of emerging technologies offering novel capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens used for basic, clinical, or epidemiological cancer research. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous technical validation to encourage adoption by the research community. Well-suited applications must propose the development of technologies that offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, epidemiology. Technologies proposed for development may have potential for widespread applicability but must be focused in this proposal on cancer-relevant use cases. Projects proposing to apply or use existing technologies for hypothesis-driven research where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Federal Grant Title:	Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-CA-27-002
Type of Funding:	Grant
CFDA Numbers:	93.394
CFDA Descriptions:	Information not provided
Current Application Deadline:	November 10th, 2026
Original Application Deadline:	November 10th, 2026
Posted Date:	June 3rd, 2026
Creation Date:	June 3rd, 2026
Archive Date:	January 9th, 2027
Total Program Funding:	$5,900,000
Maximum Federal Grant Award:	$300,000
Minimum Federal Grant Award:
Expected Number of Awards:	13
Cost Sharing or Matching:	No
Last Updated:	June 3rd, 2026

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Grant Announcement Contact: National Cancer Institute (NCI)
[email protected]
[email protected]
Similar Government Grants: • Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required); • Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 ...; • Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatme...; • Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate C...; • Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Ca...; • Image-Guided Cancer Interventions (STTR [R41/R42]); • An SBIR Initiative for Image-Guided Cancer Interventions (R43/R44); • In Vivo Cancer Imaging Exploratory/Developmental Grants
More Grants from the National Institutes of Health: • Development of Candidate Medical Countermeasures (MCMs) and Technologies Against Radiologi...; • Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required); • Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76 Clinical Trial Not ...; • Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required); • Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research (P5...